Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan

Gen Hirano, Akitaka Makiyama, Chinatsu Makiyama, Taito Esaki, Hisanobu Oda, Keita Uchino, Masato Komoda, Risa Tanaka, Yuzo Matsushita, Kenji Mitsugi, Yoshihiro Shibata, Hozumi Kumagai, Shuji Arita, Hiroshi Ariyama, Hitoshi Kusaba, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

16 引用 (Scopus)

抄録

Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.

Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.

Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).

Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.

元の言語英語
ページ(範囲)371-378
ページ数8
ジャーナルAnticancer research
35
発行部数1
出版物ステータス出版済み - 1 1 2015

Fingerprint

Colorectal Neoplasms
Japan
Survival
Anorexia
Therapeutics
Aspartate Aminotransferases
regorafenib
Alanine Transaminase
Disease-Free Survival
Fatigue
Disease Progression
Liver Diseases
Foot
Hand
Skin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Hirano, G., Makiyama, A., Makiyama, C., Esaki, T., Oda, H., Uchino, K., ... Baba, E. (2015). Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer research, 35(1), 371-378.

Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. / Hirano, Gen; Makiyama, Akitaka; Makiyama, Chinatsu; Esaki, Taito; Oda, Hisanobu; Uchino, Keita; Komoda, Masato; Tanaka, Risa; Matsushita, Yuzo; Mitsugi, Kenji; Shibata, Yoshihiro; Kumagai, Hozumi; Arita, Shuji; Ariyama, Hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.

:: Anticancer research, 巻 35, 番号 1, 01.01.2015, p. 371-378.

研究成果: ジャーナルへの寄稿記事

Hirano, G, Makiyama, A, Makiyama, C, Esaki, T, Oda, H, Uchino, K, Komoda, M, Tanaka, R, Matsushita, Y, Mitsugi, K, Shibata, Y, Kumagai, H, Arita, S, Ariyama, H, Kusaba, H, Akashi, K & Baba, E 2015, 'Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan', Anticancer research, 巻. 35, 番号 1, pp. 371-378.
Hirano G, Makiyama A, Makiyama C, Esaki T, Oda H, Uchino K その他. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. Anticancer research. 2015 1 1;35(1):371-378.
Hirano, Gen ; Makiyama, Akitaka ; Makiyama, Chinatsu ; Esaki, Taito ; Oda, Hisanobu ; Uchino, Keita ; Komoda, Masato ; Tanaka, Risa ; Matsushita, Yuzo ; Mitsugi, Kenji ; Shibata, Yoshihiro ; Kumagai, Hozumi ; Arita, Shuji ; Ariyama, Hiroshi ; Kusaba, Hitoshi ; Akashi, Koichi ; Baba, Eishi. / Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan. :: Anticancer research. 2015 ; 巻 35, 番号 1. pp. 371-378.
@article{1576f553f5d44cd1a585970bddb8aa6f,
title = "Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan",
abstract = "Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.Results: Best objective response rate was 0{\%} and stable disease (SD) was 31{\%}. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53{\%}) patients suffered grade 3 or 4 adverse events including fatigue (13{\%}), anorexia (13{\%}), hand-foot skin reaction (22{\%}) and elevations of alanine aminotransferase/aspartate aminotransferase (19{\%}/16{\%}). One patient with grade 5 liver dysfunction was identified (3{\%}). Twenty-nine (91{\%}) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59{\%}. Regorafenib treatments were terminated because of disease progression (59{\%}) or adverse events (34{\%}).Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.",
author = "Gen Hirano and Akitaka Makiyama and Chinatsu Makiyama and Taito Esaki and Hisanobu Oda and Keita Uchino and Masato Komoda and Risa Tanaka and Yuzo Matsushita and Kenji Mitsugi and Yoshihiro Shibata and Hozumi Kumagai and Shuji Arita and Hiroshi Ariyama and Hitoshi Kusaba and Koichi Akashi and Eishi Baba",
year = "2015",
month = "1",
day = "1",
language = "English",
volume = "35",
pages = "371--378",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan

AU - Hirano, Gen

AU - Makiyama, Akitaka

AU - Makiyama, Chinatsu

AU - Esaki, Taito

AU - Oda, Hisanobu

AU - Uchino, Keita

AU - Komoda, Masato

AU - Tanaka, Risa

AU - Matsushita, Yuzo

AU - Mitsugi, Kenji

AU - Shibata, Yoshihiro

AU - Kumagai, Hozumi

AU - Arita, Shuji

AU - Ariyama, Hiroshi

AU - Kusaba, Hitoshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.

AB - Background: Salvage-line regorafenib monotherapy exhibited a marked survival benefit for metastatic colorectal cancer (mCRC). However, the toxicity of this regimen has resulted in the clinical use of a reduced dose of regorafenib.Patients and Methods: Thirty-two Japanese mCRC patients (median age=61 years) who had been treated with regorafenib were retrospectively examined.Results: Best objective response rate was 0% and stable disease (SD) was 31%. Median progression-free survival was 81 days and median overall survival was 233 days. Adverse events of any grade were observed in all patients: 17 (53%) patients suffered grade 3 or 4 adverse events including fatigue (13%), anorexia (13%), hand-foot skin reaction (22%) and elevations of alanine aminotransferase/aspartate aminotransferase (19%/16%). One patient with grade 5 liver dysfunction was identified (3%). Twenty-nine (91%) patients required treatment dose reduction or a delay in treatment. The relative dose intensity was 59%. Regorafenib treatments were terminated because of disease progression (59%) or adverse events (34%).Conclusion: Despite a decrease in the intensity of regorafenib treatment, because of severe adverse events, a fairly favorable efficacy was achieved in Japanese patients.

UR - http://www.scopus.com/inward/record.url?scp=84920433770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920433770&partnerID=8YFLogxK

M3 - Article

C2 - 25550574

AN - SCOPUS:84920433770

VL - 35

SP - 371

EP - 378

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -